TNF and infection: A phase 2 randomized controlled trial evaluating the combination of guselkumab (anti-IL-23 mAb) and golimumab (anti-TNFα mAb) demonstrated significantly improved clinical response and clinical remission compared with monotherapy treatment with no difference between groups in adverse events and serious infections (103).